BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
BioCentury | Mar 14, 2020
Translation in Brief

A peptide fusion blocker for multiple coronaviruses, the cryo-EM structure of SARS-CoV-2 main protease, plus Locus, Excision and Harvard-Dana-Farber

Fudan University develops pan-coronavirus inhibitor A team led by Fudan University researchers has developed a lipopeptide-based pan-coronavirus inhibitor of viral membrane fusion. Described in a preprint on the bioRxiv server, the lipopeptide binds the SARS-CoV-2...
BioCentury | Nov 27, 2017
Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture and mouse studies suggest the GLS inhibitor CB-839 could help treat KRAS-mutant lung cancers that also harbor KEAP1 mutations. In a mouse model of KRAS- and KEAP1-mutant lung cancer, the...
BioCentury | Apr 25, 2017
Distillery Techniques

Biomarkers

...12 genomic loci, including potassium channel KCa2.2 (KCNN2) (rs337711), Nav1.8 ( PN3 ; SCN10A) (rs6800541), kelch like family member 3 (KLHL3)...
...Broad Institute of MIT and Harvard, Cambridge, Mass. email: ellinor@mgh.harvard.edu Hongjiang Li Broad Institute of MIT and Harvard Riken Kelch like family member 3 (KLHL3) N-acylsphingosine...
BioCentury | Mar 29, 2017
Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Double KEAP1 / NFE2L2 -knockout mice could be used to screen therapies for nephrogenic diabetes insipidus. Mice with systemic knockout of KEAP1 and squamous epithelium-specific knockout of NFE2L2 recapitulated the polyuria,...
BioCentury | Mar 6, 2017
Clinical News

Researchers identify KEAP1 as AD target

In a manuscript published in PLoS Genetics , U.K. researchers identified Kelch-like ECH associated protein 1 ( KEAP1 ) as a potential target to treat Alzheimer's disease. In a fly model, the scientists found that inhibition of KEAP1...
BioCentury | Nov 15, 2016
Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Mice expressing a human mutation in human kelch like family member 24 (KLHL24) could be used to screen therapies for epidermolysis bullosa. Whole-genome sequencing of three related patients and two unrelated...
BioCentury | Oct 8, 2015
Distillery Therapeutics

Therapeutics: Kelch-like ECH-associated protein 1 (KEAP1); nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

Hematology INDICATION: Sickle cell disease Mouse studies suggest inhibiting KEAP1 or activating NFE2L2 could help treat sickle cell disease. In a mouse model of sickle cell disease, KEAP1 knockdown increased NFE2L2 levels in the liver...
BioCentury | Sep 24, 2015
Distillery Therapeutics

Therapeutics: Kelch-like ECH-associated protein 1 (KEAP1); nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

Inflammation INDICATION: Inflammation In vitro and mouse studies suggest inhibiting the KEAP1- NFE2L2 interaction could help treat inflammation. Disassociation of the KEAP1-NFE2L2 complex activates NFE2L2-mediated antioxidant responses. Chemical synthesis and testing in KEAP1-NFE2L2 binding assays...
BioCentury | Nov 6, 2014
Distillery Techniques

Technology: Computational models

Approach Summary Licensing status Publication and contact information Computational models Driver-gene inference by genetic-genomics and information theory (DIGGIT) algorithm to identify disease driver mutations In vitro studies suggest network-based analysis with DIGGIT could help identify...
Items per page:
1 - 10 of 16